Omada (OMDA) Q2 2025 earnings

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Omada Health reported quarterly results for the first time since its initial public offering in June. Here’s how the company did based on average analysts’ estimates compiled by LSEG: Loss per share: 24 cents Revenue: $61 million vs. $55.2…

Read More

Eli Lilly (LLY) Q2 2025 earnings report

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business….

Read More

Trump administration to pilot covering obesity drugs

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For…

Read More

Hims & Hers (HIMS) Q2 earnings 2025

The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025.  Gabby Jones | Bloomberg | Getty Images Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue. Here’s how the company did…

Read More

Moderna (MRNA) Q2 2025 earnings

Moderna logo is seen in Warsaw, Poland on April 9, 2025. Jakub Porzycki | Nurphoto | Getty Images Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs….

Read More